iShares Neuroscience and Healthcare ETF
IBRN
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 400 Howard Street San Francisco CA United States of America 94105
- IPO Date
- Aug 29, 2022
- Website
- ishares.com
- Similar Companies
- Business
- iShares Neuroscience and Healthcare ETF (IBRN) is an exchange-traded fund that seeks to track the investment results of an index composed of global equities in the neuroscience and healthcare sectors. The ETF provides exposure to companies engaged in the research, development, and commercialization of treatments and technologies targeting neurological disorders and healthcare innovations; this includes pharmaceuticals, biotechnology firms, medical devices, and diagnostics focused on areas such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and related therapeutic advancements. IBRN offers investors diversified access to small-, mid-, and large-cap stocks selected based on their involvement in neuroscience innovation, with holdings weighted by market capitalization and subject to liquidity and other index criteria. Managed by BlackRock, Inc. under the iShares brand, the fund was launched in 2019 and is domiciled in the United States with primary listing on the BATS Exchange. It operates globally, with underlying holdings spanning North America, Europe, and Asia-Pacific regions, targeting institutional and retail investors interested in thematic healthcare equity strategies. The ETF employs a full replication strategy to mirror the S&P Kensho Neuroscience ETF Index, rebalanced quarterly to reflect sector developments. In recent developments, IBRN benefited from heightened investor interest in neuroscience amid clinical trial advancements and regulatory approvals for novel therapies in 2024-2025, including partnerships between portfolio companies and big pharma for gene therapies targeting rare neurological conditions. BlackRock expanded the iShares thematic ETF suite with complementary funds, enhancing distribution through strategic alliances with financial advisors; no major acquisitions or name changes occurred, though assets under management grew significantly due to inflows amid rising demand for precision medicine exposures. The fund maintains a low expense ratio of 0.47%, positioning it competitively within specialized healthcare ETFs.